Skip to content

Study · Animal study (in vivo) · rat · 2021

8 results

Occlusion of the Superior Mesenteric Artery in Rats Reversed by Collateral Pathways Activation: Gastric Pentadecapeptide BPC 157 Therapy Counteracts Multiple Organ Dysfunction Syndrome; Intracranial, Portal, and Caval Hypertension; and Aortal Hypotension.

Knezevic M, Gojkovic S, Krezic I, Zizek H, Malekinusic D, Vrdoljak B, Vranes H, Knezevic T, Barisic I, Horvat Pavlov K, Drmic D, Staroveski M and 15 more

Show all authors

Djuzel A, Rajkovic Z, Kolak T, Kocman I, Lovric E, Milavic M, Sikiric S, Tvrdeic A, Patrlj L, Strbe S, Kokot A, Boban Blagaic A, Skrtic A, Seiwerth S, Sikiric P

Biomedicines26 May 2021Cited by 31 (Europe PMC)

PMID34073625 (opens in a new tab)PMCIDPMC8229949 (opens in a new tab)DOI10.3390/biomedicines9060609 (opens in a new tab)PepBankPUB-34073625
Download PDFPubMedAsk about this study
Jump to 8 results

Summary

Gastric pentadecapeptide BPC 157 therapy counteracts multiple organ dysfunction syndrome in rats, which have permanent occlusion of the superior mesenteric artery close to the abdominal aorta. Previously, when confronted with major vessel occlusion, its effect would rapidly activate collateral vessel pathways and resolve major venous occlusion syndromes (Pringle maneuver ischemia, reperfusion, Budd-Chiari syndrome) in rats. This would overwhelm superior mesenteric artery permanent occlusion, and result in local, peripheral, and central disturbances. Methods: Assessments, for 30 min (gross recording, angiography, ECG, pressure, microscopy, biochemistry, and oxidative stress), included the portal hypertension, caval hypertension, and aortal hypotension, and centrally, the superior sagittal sinus hypertension; systemic arterial and venous thrombosis; ECG disturbances; MDA-tissue increase; and multiple organ lesions and disturbances, including the heart, lung, liver, kidney, and gastrointestinal tract, in particular, as well as brain (cortex (cerebral, cerebellar), hypothalamus/thalamus, hippocampus). BPC 157 therapy (/kg, abdominal bath) (10 µg, 10 ng) was given for a 1-min ligation time. Results: BPC 157 rapidly recruits collateral vessels (inferior anterior pancreaticoduodenal artery and inferior mesenteric artery) that circumvent occlusion and ascertains blood flow distant from the occlusion in the superior mesenteric artery. Portal and caval hypertension, aortal hypotension, and, centrally, superior sagittal sinus hypertension were attenuated or eliminated, and ECG disturbances markedly mitigated. BPC 157 therapy almost annihilated venous and arterial thrombosis. Multiple organ lesions and disturbances (i.e., heart, lung, liver, and gastrointestinal tract, in particular, as well as brain) were largely attenuated. Conclusions: Rats with superior mesenteric artery occlusion may additionally undergo BPC 157 therapy as full counteraction of vascular occlusion-induced multiple organ dysfunction syndrome.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study8

8 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with superior mesenteric artery occlusion, BPC‑157 rapidly recruited collateral vessels that circumvent the occlusion and ascertain blood flow.

    In plain wordsIn rats with a blocked abdominal artery, BPC‑157 quickly opened extra vessels so blood could flow around the block.

    Peptide
    BPC-157
    Outcome
    IncreaseCollateral vessel recruitment and blood flow distant from the occlusion
    Study

    ratn: not reported in source

    Permanent occlusion of the superior mesenteric artery
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    10 µg/kg and 10 ng/kg · abdominal bathAs given in this study (rat).

    Source sentences

    Summary
    BPC 157 rapidly recruits collateral vessels (inferior anterior pancreaticoduodenal artery and inferior mesenteric artery) that circumvent occlusion and ascertains blood flow distant from the occlusion in the superior mesenteric artery.
    2 context sentences
    Summary · context
    Gastric pentadecapeptide BPC 157 therapy counteracts multiple organ dysfunction syndrome in rats, which have permanent occlusion of the superior mesenteric artery close to the abdominal aorta.
    Summary · context
    BPC 157 therapy (/kg, abdominal bath) (10 µg, 10 ng) was given for a 1-min ligation time.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats with superior mesenteric artery occlusion, portal and caval hypertension were attenuated or eliminated with BPC‑157.

    In plain wordsIn rats with a blocked abdominal artery, BPC‑157 reduced or removed high pressure in two large abdominal veins.

    Peptide
    BPC-157
    Outcome
    DecreasePortal and caval hypertension
    Study

    ratn: not reported in source

    Permanent occlusion of the superior mesenteric artery
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    10 µg/kg and 10 ng/kg · abdominal bathAs given in this study (rat).

    Source sentences

    Summary
    Portal and caval hypertension
    3 context sentences
    Summary · context
    were attenuated or eliminated
    Summary · context
    Gastric pentadecapeptide BPC 157 therapy counteracts multiple organ dysfunction syndrome in rats, which have permanent occlusion of the superior mesenteric artery close to the abdominal aorta.
    Summary · context
    BPC 157 therapy (/kg, abdominal bath) (10 µg, 10 ng) was given for a 1-min ligation time.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats with superior mesenteric artery occlusion, aortal hypotension was attenuated or eliminated with BPC‑157.

    In plain wordsIn rats with a blocked abdominal artery, BPC‑157 reduced or removed the low aortic pressure.

    Peptide
    BPC-157
    Outcome
    IncreaseAortal hypotension
    Study

    ratn: not reported in source

    Permanent occlusion of the superior mesenteric artery
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    10 µg/kg and 10 ng/kg · abdominal bathAs given in this study (rat).

    Source sentences

    Summary
    aortal hypotension, and, centrally, superior sagittal sinus hypertension were attenuated or eliminated
    2 context sentences
    Summary · context
    Gastric pentadecapeptide BPC 157 therapy counteracts multiple organ dysfunction syndrome in rats, which have permanent occlusion of the superior mesenteric artery close to the abdominal aorta.
    Summary · context
    BPC 157 therapy (/kg, abdominal bath) (10 µg, 10 ng) was given for a 1-min ligation time.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats with superior mesenteric artery occlusion, superior sagittal sinus hypertension was attenuated or eliminated with BPC‑157.

    In plain wordsIn rats with a blocked abdominal artery, BPC‑157 reduced or removed raised pressure in the brain's main vein.

    Peptide
    BPC-157
    Outcome
    DecreaseSuperior sagittal sinus hypertension
    Study

    ratn: not reported in source

    Permanent occlusion of the superior mesenteric artery
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    10 µg/kg and 10 ng/kg · abdominal bathAs given in this study (rat).

    Source sentences

    Summary
    superior sagittal sinus hypertension were attenuated or eliminated
    2 context sentences
    Summary · context
    Gastric pentadecapeptide BPC 157 therapy counteracts multiple organ dysfunction syndrome in rats, which have permanent occlusion of the superior mesenteric artery close to the abdominal aorta.
    Summary · context
    BPC 157 therapy (/kg, abdominal bath) (10 µg, 10 ng) was given for a 1-min ligation time.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In rats with superior mesenteric artery occlusion, ECG disturbances were markedly mitigated with BPC‑157.

    In plain wordsIn rats with a blocked abdominal artery, BPC‑157 clearly reduced heart rhythm trace disturbances.

    Peptide
    BPC-157
    Outcome
    DecreaseECG disturbances
    Study

    ratn: not reported in source

    Permanent occlusion of the superior mesenteric artery
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    10 µg/kg and 10 ng/kg · abdominal bathAs given in this study (rat).

    Source sentences

    Summary
    ECG disturbances markedly mitigated.
    2 context sentences
    Summary · context
    Gastric pentadecapeptide BPC 157 therapy counteracts multiple organ dysfunction syndrome in rats, which have permanent occlusion of the superior mesenteric artery close to the abdominal aorta.
    Summary · context
    BPC 157 therapy (/kg, abdominal bath) (10 µg, 10 ng) was given for a 1-min ligation time.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In rats with superior mesenteric artery occlusion, BPC‑157 therapy almost annihilated venous and arterial thrombosis.

    In plain wordsIn rats with a blocked abdominal artery, BPC‑157 almost removed blood clots in veins and arteries.

    Peptide
    BPC-157
    Outcome
    DecreaseVenous and arterial thrombosis
    Study

    ratn: not reported in source

    Permanent occlusion of the superior mesenteric artery
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    10 µg/kg and 10 ng/kg · abdominal bathAs given in this study (rat).

    Source sentences

    Summary
    BPC 157 therapy almost annihilated venous and arterial thrombosis.
    2 context sentences
    Summary · context
    Gastric pentadecapeptide BPC 157 therapy counteracts multiple organ dysfunction syndrome in rats, which have permanent occlusion of the superior mesenteric artery close to the abdominal aorta.
    Summary · context
    BPC 157 therapy (/kg, abdominal bath) (10 µg, 10 ng) was given for a 1-min ligation time.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In rats with superior mesenteric artery occlusion, lesions of the heart, lung, liver and gastrointestinal tract were largely attenuated with BPC‑157.

    In plain wordsIn rats with a blocked abdominal artery, BPC‑157 largely reduced damage to the heart, lungs, liver and gut.

    Peptide
    BPC-157
    Outcome
    DecreaseMultiple organ lesions (heart, lung, liver, gastrointestinal tract)
    Study

    ratn: not reported in source

    Permanent occlusion of the superior mesenteric artery
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    10 µg/kg and 10 ng/kg · abdominal bathAs given in this study (rat).

    Source sentences

    Summary
    Multiple organ lesions and disturbances (i.e., heart, lung, liver, and gastrointestinal tract, in particular, as well as brain) were largely attenuated.
    2 context sentences
    Summary · context
    Gastric pentadecapeptide BPC 157 therapy counteracts multiple organ dysfunction syndrome in rats, which have permanent occlusion of the superior mesenteric artery close to the abdominal aorta.
    Summary · context
    BPC 157 therapy (/kg, abdominal bath) (10 µg, 10 ng) was given for a 1-min ligation time.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In rats with superior mesenteric artery occlusion, brain lesions were largely attenuated with BPC‑157.

    In plain wordsIn rats with a blocked abdominal artery, BPC‑157 largely reduced brain damage.

    Peptide
    BPC-157
    Outcome
    DecreaseBrain lesions
    Study

    ratn: not reported in source

    Permanent occlusion of the superior mesenteric artery
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    10 µg/kg and 10 ng/kg · abdominal bathAs given in this study (rat).

    Source sentences

    Summary
    Multiple organ lesions and disturbances (i.e., heart, lung, liver, and gastrointestinal tract, in particular, as well as brain) were largely attenuated.
    2 context sentences
    Summary · context
    Gastric pentadecapeptide BPC 157 therapy counteracts multiple organ dysfunction syndrome in rats, which have permanent occlusion of the superior mesenteric artery close to the abdominal aorta.
    Summary · context
    BPC 157 therapy (/kg, abdominal bath) (10 µg, 10 ng) was given for a 1-min ligation time.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.